Thermo Fisher Scientific (NYSE:TMO) Given New $632.00 Price Target at Robert W. Baird

Thermo Fisher Scientific (NYSE:TMO) had its target price hoisted by Robert W. Baird from $620.00 to $632.00 in a report issued on Thursday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

Several other equities analysts also recently commented on TMO. Barclays decreased their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an equal weight rating on the stock in a research report on Friday, June 28th. Evercore ISI dropped their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an outperform rating for the company in a research note on Tuesday, July 2nd. HSBC increased their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a buy rating in a report on Tuesday, April 30th. JPMorgan Chase & Co. increased their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an overweight rating in a report on Thursday, April 25th. Finally, Jefferies Financial Group restated a buy rating and issued a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of Moderate Buy and a consensus target price of $618.94.

Thermo Fisher Scientific Stock Up 2.1 %

NYSE TMO opened at $607.14 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.33 and a current ratio of 1.72. Thermo Fisher Scientific has a 52 week low of $415.60 and a 52 week high of $614.65. The stock has a fifty day moving average of $563.01 and a 200-day moving average of $565.97. The stock has a market capitalization of $231.76 billion, a P/E ratio of 38.94, a price-to-earnings-growth ratio of 2.83 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same period in the previous year, the company posted $5.15 earnings per share. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. On average, equities research analysts forecast that Thermo Fisher Scientific will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds have recently modified their holdings of the company. IFG Advisory LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $220,000. Altfest L J & Co. Inc. increased its holdings in Thermo Fisher Scientific by 116.7% in the 4th quarter. Altfest L J & Co. Inc. now owns 1,573 shares of the medical research company’s stock valued at $835,000 after acquiring an additional 847 shares during the last quarter. Ritholtz Wealth Management increased its holdings in shares of Thermo Fisher Scientific by 7.0% in the 4th quarter. Ritholtz Wealth Management now owns 3,908 shares of the medical research company’s stock worth $2,074,000 after buying an additional 254 shares during the last quarter. Clear Harbor Asset Management LLC boosted its stake in shares of Thermo Fisher Scientific by 8.5% during the 4th quarter. Clear Harbor Asset Management LLC now owns 10,816 shares of the medical research company’s stock worth $5,741,000 after purchasing an additional 850 shares during the period. Finally, McGlone Suttner Wealth Management Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $96,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.